The Role of Growth Factors in Bioactive Coatings

Abstract

With increasing obesity and an ageing population, health complications are also on the rise, such as the need to replace a joint with an artificial one. In both humans and animals, the integration of the implant is crucial, and bioactive coatings play an important role in bone tissue engineering. Since bone tissue engineering is about designing an implant that maximally mimics natural bone and is accepted by the tissue, the search for optimal materials and therapeutic agents and their concentrations is increasing. The incorporation of growth factors (GFs) in a bioactive coating represents a novel approach in bone tissue engineering, in which osteoinduction is enhanced in order to create the optimal conditions for the bone healing process, which crucially affects implant fixation. For the application of GFs in coatings and their implementation in clinical practice, factors such as the choice of one or more GFs, their concentration, the coating material, the method of incorporation, and the implant material must be considered to achieve the desired controlled release. Therefore, the avoidance of revision surgery also depends on the success of the design of the most appropriate bioactive coating. This overview considers the integration of the most common GFs that have been investigated in in vitro and in vivo studies, as well as in human clinical trials, with the aim of applying them in bioactive coatings. An overview of the main therapeutic agents that can stimulate cells to express the GFs necessary for bone tissue development is also provided. The main objective is to present the advantages and disadvantages of the GFs that have shown promise for inclusion in bioactive coatings according to the results of numerous studies.

Keywords: bioactive coating; bone tissue; controlled local release; growth factor; implant; osseointegration.

Figure 1

Release profiles of BMP-2 from PLA coating (PLA-BMP) and PLA coating with the addition of polydopamine (PLA-PD-BMP). Reprinted (adapted) with permission from [53], American Chemical Society, 2018.

Figure 2

Schematic representation of the formation of the ternary complex. The components are pDNA, polyethyleneimine (PEI), and a polyanion. Reprinted with permission from [146], Elsevier, 2009.

Figure 3

The process of heparinization, the loading of BMP-7 and BMP-2, and release. Reprinted with permission from [149], Elsevier, 2015.

Figure 4

A schematic presentation of the components and structure of the multilayer coating described in [93]. Reprinted with permission from [93], American Chemical Society, 2017. https://pubs.acs.org/doi/full/10.1021/acsomega.6b00420 (accessed on 3 December 2020).

Figure 5

Schematic representation of the heparinization and immobilization of bFGF. PG represents the PCL/gelatin fibrous matrices cross-linked with genipin, PH represents PG fibers conjugated with heparin, and PH FGF represents a coating with immobilized bFGF. Reprinted with permission from [155], John Wiley and Sons, 2011.

Figure 6

Release profiles of BMP-2 and IGF-1 (C) from a scaffold containing adsorbed GFs and (F) from a scaffold containing microparticles with loaded GFs. Reprinted (adapted) with permission from [106], Elsevier, 2009.

Figure 7

The release profile of VEGF from Ti6Al4V implant material, implant material with a collagen coating, implant material with a heparin-cross-linked collagen coating, and implant material with a heparin-incorporated collagen coating. Reprinted with permission from [120], John Wiley and Sons, 2006.

Figure 8

Schematic representation of the probable molecular mechanism of Zn-modified coatings, inducing the expression of genes required for cell differentiation from BMP-PC to osteoblasts via the TGF-β/Smad pathway. Reprinted with permission from [191], Springer Nature, 2017.